Nucorion - Overview November 1, 2020
Nucorion Pharmaceuticals Announces Closing of $5 m Series B Financing and Clinical Plan for Novel Liver-Targeting Hepatitis B Program (NCO-1010)
Nucorion Pharmaceuticals Presents Preclinical Data for its Novel Liver-Targeting Hepatitis B Program at The European Association for the Study of the Liver’s International Liver Congress™
